Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a ...

A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

Philips has begun rolling out a major update to its cardiovascular ultrasound systems, incorporating a host of imaging ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first ...

The personalized orthopedic implant maker restor3d has raised a total of $104 million to boost its commercial plans across ...

Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its ...

Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for ...

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected ...

Chinese contract research and manufacturing outfit ChemPartner is building out its U.S. footprint in the heart of the ...